| GATE: a simulation toolkit for PET and SPECT S Jan, G Santin, D Strul, S Staelens, K Assié, D Autret, S Avner, R Barbier, ... Physics in Medicine & Biology 49 (19), 4543, 2004 | 2659 | 2004 |
| Monitoring of Early Response to Neoadjuvant Chemotherapy in Stage II and III Breast Cancer by [18F]Fluorodeoxyglucose Positron Emission Tomography C Rousseau, A Devillers, C Sagan, L Ferrer, B Bridji, L Campion, ... Journal of clinical oncology 24 (34), 5366-5372, 2006 | 393 | 2006 |
| ARRONAX, a high-energy and high-intensity cyclotron for nuclear medicine F Haddad, L Ferrer, A Guertin, T Carlier, N Michel, J Barbet, JF Chatal European Journal of Nuclear Medicine and Molecular Imaging 35, 1377-1387, 2008 | 165 | 2008 |
| Targeting, toxicity, and efficacy of 2-step, pretargeted radioimmunotherapy using a chimeric bispecific antibody and 131I-labeled bivalent hapten in a phase I optimization … F Kraeber-Bodéré, C Rousseau, C Bodet-Milin, L Ferrer, ... Journal of Nuclear Medicine 47 (2), 247-255, 2006 | 146 | 2006 |
| Nuclear medical imaging using β+ γ coincidences from 44Sc radio-nuclide with liquid xenon as detection medium C Grignon, J Barbet, M Bardiès, T Carlier, JF Chatal, O Couturier, ... Nuclear Instruments and Methods in Physics Research Section A: Accelerators …, 2007 | 129 | 2007 |
| Radioimmunotherapy in medullary thyroid cancer using bispecific antibody and iodine 131-labeled bivalent hapten: preliminary results of a phase I/II clinical trial F Kraeber-Bodéré, S Bardet, CA Hoefnagel, MR Vieira, JP Vuillez, ... Clinical cancer research 5 (10), 3190s-3198s, 1999 | 119 | 1999 |
| Assessment of acquisition protocols for routine imaging of Y-90 using PET/CT T Carlier, T Eugène, C Bodet-Milin, E Garin, C Ansquer, C Rousseau, ... EJNMMI research 3, 1-12, 2013 | 96 | 2013 |
| High frequency of bone/bone marrow involvement in advanced medullary thyroid cancer E Mirallie, JP Vuillez, S Bardet, E Frampas, B Dupas, L Ferrer, ... The Journal of Clinical Endocrinology & Metabolism 90 (2), 779-788, 2005 | 92 | 2005 |
| Radioimmunoconjugates for the treatment of cancer F Kraeber-Bodéré, C Bodet-Milin, C Rousseau, T Eugène, A Pallardy, ... Seminars in oncology 41 (5), 613-622, 2014 | 88 | 2014 |
| Monte Carlo modeling of gamma cameras for I-131 imaging in targeted radiotherapy D Autret, A Bitar, L Ferrer, A Lisbona, M Bardiès Cancer biotherapy & radiopharmaceuticals 20 (1), 77-84, 2005 | 85 | 2005 |
| Effect of patient morphology on dosimetric calculations for internal irradiation as assessed by comparisons of Monte Carlo versus conventional methodologies A Divoli, S Chiavassa, L Ferrer, J Barbet, GD Flux, M Bardies Journal of Nuclear Medicine 50 (2), 316-323, 2009 | 82 | 2009 |
| Pharmacokinetics and dosimetry studies for optimization of anti-carcinoembryonic antigen× anti-hapten bispecific antibody-mediated pretargeting of iodine-131-labeled hapten in … F Kraeber-Bodéré, A Faivre-Chauvet, L Ferrer, JP Vuillez, PY Brard, ... Clinical cancer research 9 (10), 3973s-3981s, 2003 | 71 | 2003 |
| FDG PET evaluation of early axillary lymph node response to neoadjuvant chemotherapy in stage II and III breast cancer patients C Rousseau, A Devillers, M Campone, L Campion, L Ferrer, C Sagan, ... European journal of nuclear medicine and molecular imaging 38, 1029-1036, 2011 | 68 | 2011 |
| Dosimetry results suggest feasibility of radioimmunotherapy using anti-CD138 (B-B4) antibody in multiple myeloma patients C Rousseau, L Ferrer, S Supiot, M Bardiès, F Davodeau, ... Tumor Biology 33, 679-688, 2012 | 61 | 2012 |
| Voxeldose: a computer program for 3-D dose calculation in therapeutic nuclear medicine I Gardin, LG Bouchet, K Assié, J Caron, A Lisbona, L Ferrer, WE Bolch, ... Cancer Biotherapy and Radiopharmaceuticals 18 (1), 109-115, 2003 | 60 | 2003 |
| Comparison of electron dose-point kernels in water generated by the Monte Carlo codes, PENELOPE, GEANT4, MCNPX, and ETRAN H Uusijärvi, N Chouin, P Bernhardt, L Ferrer, M Bardies, ... Cancer biotherapy and radiopharmaceuticals 24 (4), 461-467, 2009 | 58 | 2009 |
| Single-dose anti-CD138 radioimmunotherapy: bismuth-213 is more efficient than lutetium-177 for treatment of multiple myeloma in a preclinical model N Fichou, S Gouard, C Maurel, J Barbet, L Ferrer, A Morgenstern, ... Frontiers in Medicine 2, 76, 2015 | 56 | 2015 |
| Three methods assessing red marrow dosimetry in lymphoma patients treated with radioimmunotherapy L Ferrer, F Kraeber‐Bodéré, C Bodet‐Milin, C Rousseau, SL Gouill, ... Cancer 116 (S4), 1093-1100, 2010 | 54 | 2010 |
| Prospective comparison of 3 γ-probes for sentinel lymph node detection in 200 breast cancer patients JM Classe, M Fiche, C Rousseau, C Sagan, F Dravet, R Pioud, A Lisbona, ... Journal of Nuclear Medicine 46 (3), 395-399, 2005 | 54 | 2005 |
| Implementing dosimetry in GATE: Dose-point kernel validation with GEANT4 4.8. 1 L Ferrer, N Chouin, A Bitar, A Lisbona, M Bardiès Cancer biotherapy & radiopharmaceuticals 22 (1), 125-129, 2007 | 51 | 2007 |
Albert LisbonaInstitut de cancérologie de l'Ouest René GauducheauCorreu electrònic verificat a ico.unicancer.fr